Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-816-9 | CAS number: 74-86-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Acetylene has low inhalation toxicity, the LOAEC for mild intoxication in humans with no residual effects is 107,000 mg/m3. There are no data on oral and dermal toxicity (studies are not technically feasible as the substance is a gas at room temperature).
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Limitations with regard to the test method and/or reporting but contributing to a weight of evidence approach
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- No details of principles of method given
- GLP compliance:
- no
- Test type:
- other: single exposure of at least 2 hours
- Limit test:
- no
- Species:
- rat
- Strain:
- other: white rat (strain not specified)
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- Single strain of white rats of uniform weight used.
- Route of administration:
- inhalation: gas
- Type of inhalation exposure:
- not specified
- Vehicle:
- other: air
- Details on inhalation exposure:
- Duration and method of exposure not reported
- Analytical verification of test atmosphere concentrations:
- not specified
- Remarks on duration:
- not reported
- Concentrations:
- Various concentrations, including 78% and 90% acetylene.
- No. of animals per sex per dose:
- Not reported
- Control animals:
- not specified
- Details on study design:
- The anaesthetic potency and toxicity of various concentrations of acetylene was assessed
- Dose descriptor:
- other: respiratory failure
- Effect level:
- 90 other: %
- Remarks on result:
- other: 963,000 mg/m3. Within about 2 hours of the start of exposure (It is assumed this concentration was lethal)
- Dose descriptor:
- other: anaesthesia
- Effect level:
- 78 other: %
- Remarks on result:
- other: 834,600 mg/m3. Induced anaesthesia within 15 minutes of the start of exposure but this was not preceded by a marked excitement stage.
- Mortality:
- Respiratory failure within 2 hours, group size not reported
- Clinical signs:
- other: Not reported
- Body weight:
- Not reported
- Gross pathology:
- Not reported
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Inhalation LC50 rats between 78% - 90% acetylene
equivalent to LC50 780,000 - 900,000 ppm - Executive summary:
The inhalation toxicity of acetylene was investigated in rats. 78% induced anaesthesia within 15 minutes and 90% caused respiratory failure within 2 hours.
Inhalation LC50 rats between 78% - 90% acetylene, equivalent to LC50 780,000 - 900,000 ppm (834,600 - 963,000 mg/m3)
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 834 600 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Non-human information
Acute toxicity: oral
No data available (acetylene is a gas at room temperature and therefore a study does not need to be conducted).
Acute toxicity: inhalation
There are a number of studies providing weight of evidence for low toxicity via the inhalation route in animals. There is no evidence of acute toxicity below the lower explosive limit (LEL) of acetylene which is 2.5% equivalent to 25,000 ppm (UK HPA, 2009).
Heymans & Bouckaert (1925) exposed dogs by inhalation to atmospheres of 850,000 ppm acetylene for up to 3 hours. Animals showed increases in respiratory volume and frequency and anaesthesia but quickly recovered following removal from atmosphere and there was no mortality. This indicates the acute inhalation LC50 > 850000ppm (909,500 mg/m3).
These findings are supported by Riggs L (1925) who investigated the inhalation toxicity of acetylene in rats. Acetylene air concentrations of 78% induced anaesthesia within 15 minutes and 90% caused respiratory failure within 2 hours. The acute inhalation LC50 rats is therefore estimated to be between 78% - 90% acetylene (equivalent to LC50 834,600 – 963,000 mg/m3)
The toxicokinetics study reported by Ortiz de Montellano & Kunze (1980) (see 5.1.1 above) involved exposure of rats to 10-15% acetylene for 4 hours which they all survived (i.e. no lethality at 15% equivalent to 160,500 mg/m3). Another of the toxicokinetic studies involved exposure of rats to 5% acetylene (53,500 mg/m3) for 18 hours with no mortality reported (White, 1978).
Considering repeated dose toxicity (see 5.6.3 below), there were no mortalities after 14 and 10 days exposure in rats and guinea pigs (exposure 1 h/day) at 80% acetylene (856,000 mg/m3) (Franken & Miklos, 1933). Although a higher death rate was reported in rats exposed to 25% acetylene, this was over the period 7-93 days.
Acute toxicity: dermal
No data available (acetylene is a gas at room temperature and therefore a study does not need to be conducted).
Acute toxicity: other routes
No data available
Human information
Acetylene is viewed as a simple asphyxiant, reducing the amount of oxygen available. Inhalation of acetylene may result in dizziness, headache, weakness, nausea and vomiting (UK HPA, 2009).
As early as the mid 1920’s it had been reported that acetylene had been successfully used, at very high concentrations, as an anaesthetic in over 2,000 surgical procedures in humans without significant adverse effects (Horwitz, 1923, Davidson, 1925; Goldman and Goldman, 1925; Brandt, 1926, Franken and Schurmeyer, 1928 and Franken, 1930). Alveolar concentration that would result in unconsciousness is, on average, 35% with the concentrations required for anaesthesia for surgery being generally between 70 and 80% (i.e. up to 856,000 mg/m3) (Adriani, 1979).
A group of human volunteers were exposed to acetylene at a range of concentrations in order to assess its anaesthetic properties (Davidson, 1925). The lowest concentration employed, 10%, caused feelings of mild intoxication and paraesthesia.
Therefore the systemic LOAEC following 1 hour inhalation exposure is considered to be 10% (100,000 ppm or 107,000 mg/m3 equivalent).Today, the gas is still used in medicine and sport physiology and cardiology but in a rather different way. It is used as part of a clinical technique, often referred to as the inert gas re-breathing technique, to estimate cardiac output. The inert gases used are acetylene, or carbon dioxide or nitrous oxide and when acetylene is used as the blood-soluble inert gas, it is often called the acetylene re-breathing technique. There is a significant amount of literature reporting this procedure by investigators attempting to further understanding of cardiac output changes in humans during, for example, exercise, aging, existence at high altitude, zero gravity, cardiovascular illness and pregnancy and postpartum (Bell et al, 2003; Bell et al, 2001; Warburton et al, 1998; Pierson et al, 2003; Eakin et al, 1993; Johnson et al, 1999; Petrine et al, 1978; Triebwasser et al, 1977; Nystrom et al, 1986; Hoeper et al 1999; Sady et al, 1989; Carpenter et al, 1990; Bogaard and Wagner, 2006).
Typically (Hoeper et al, 1999), with nostrils occluded, a re-breathing bag is filled with a gas mixture, for example, of oxygen nitrogen, carbon monoxide helium and acetylene (3%; 3210 mg/m3). The total bag volume is about 60% of the patient’s vital capacity. The patient completely empties the bag in about 30 s. Cardiac output can be calculated from the rate of disappearance of acetylene from expired air (often measured by mass spectrometry). No reports of significant adverse effects in humans, associated with the acetylene re-breathing procedure have been found in any publications reviewed.
Additional citations
Bell, C et al (2001). Use of Open-Circuit Acetylene Breathing To Estimate Sub-Maximal and Maximal Cardiac Output: Comparison With Closed-Circuit Acetylene Re-Breathing. Medicine & Science in Sports & Exercise. 33(5): S300.
Bell, C et al (2003). Use of Acetylene Breathing to Determine Cardiac Output in Young and Older Adults. Medicine & Science in Sports & Exercise. 35(1):58-64.
Bogaard HM & Wagner PD (2006). Measurement of cardiac output by open-circuit acetylene uptake: a computer model to quantify error caused by ventilation–perfusion inequality.. Physiol. Meas.271023-1032.
Brandt T, (1926). Acetylene-oxygen anesthesia is gastric surgery. Anesth. Analg. (Cleveland) 5: 329-36.
Carpenter MW et al (1990). . Effect of maternal weight gain during pregnancy on exercise performance. Journal of Applied Physiology, Vol 68, Issue 3 1173-1176
Eakin, BL et al (1993). Validation of Acetylene Rebreathing Cardiac Outputs in Adolescents With Congenital Heart Disease Medicine & Science in Sports & Exercise. 25(5): S84.
Franken H & Schurmeyer A, (1928). (Collapse and anaesthesia – Determining the circulatory blood volume during ether, avertin, and acetylene anaesthesia and its significance). In German. Nark. Anaesth. 1, 437 – 447.
Franken H (1930). Respiration, circulation and musculature during narcosis – Studies on behaviour and effects in man and animals. In German. Arch. Gynaekol. 140, 496 – 553.
Goldman A and GoldmanJD, (1925). Anesth. Analg. (Cleveland) 4, 211 – 218.
Hoeper MM et al (1999). Determination of Cardiac Output by the Fick Method, Thermodilution, and Acetylene Rebreathing in Pulmonary Hypertension. Am. J. Respir. Crit. Care Med., Volume 160, Number 2, 535-541.
Horwitz CS (1923). A new general anaesthetic. Lancet Vol. 201, No. 5195, p619. Horwitz, 1923
Johnson, B et al (1999). Open Circuit Acetylene Wash-in Technique for Determining Cardiac Output During Exercise: Comparison With Direct Fick. Medicine & Science in Sports & Exercise. 31(5): S58.
Nyström J et al (1986). Evaluation of a modified acetylene rebreathing method for the determination of cardiac output. Clin. Physiol. 6: 253 - 268.
Petrini MF et al (1978). Lung tissue volume and blood flow by rebreathing: theory. J. Appl. Physiol. 44: 795-802.
Pierson, LM et al (2003). Reproducibility of Cardiac Output in Ramping Exercise Measured By Acetylene Single-Breath Technique. Medicine & Science in Sports & Exercise. 35(5): S143.
Sady, SP et al (1989). Cardiovascular response to cycle exercise during and after pregnancy. J. Appl. Physiol. 66(l): 336-341.
Triebwasser JH et al (1977). Non-invasive determination of cardiac output by a modified acetylene rebreathing procedure utilizing mass spectrometer measurements. Aviat. Space Environ. Med. 46: 203-209.
UK HPA (2009): Compendium of Chemical Hazards: Acetylene
Warburton,DERet al (1998). Reproducibility of the acetylene rebreathe technique for determining cardiac output. Medicine & Science in Sports & Exercise. 30(6):952-957.
Justification for selection of acute toxicity – inhalation endpoint
Respiratory failure in rats, the acute inhalation LC50 estimated to be between 78% - 90% acetylene (equivalent to LC50 834,600 – 963,000 mg/m3). This exceeds the threshold for classification. Therefore, although an effect has been identified, this is not considered relevant for the establishment of a DNEL.
Justification for classification or non-classification
Acetylene does not warrant classification under CLP for acute toxicity via oral, inhalation (LC50 well in excess of LEL of 2.5% and the threshold for classification) or dermal routes of exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.